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Abstract
Pathogenic Leptospira spp. shed in the urine of reservoir hosts into freshwater can be transmitted to a susceptible host
through skin abrasions or mucous membranes causing leptospirosis. The infection process involves the ability of leptospires
to adhere to cell surface and extracellular matrix components, a crucial step for dissemination and colonization of host
tissues. Therefore, the elucidation of novel mediators of host-pathogen interaction is important in the discovery of virulence
factors involved in the pathogenesis of leptospirosis. In this study, we assess the functional roles of transmembrane outer
membrane proteins OmpL36 (LIC13166), OmpL37 (LIC12263), and OmpL47 (LIC13050), which we recently identified on the
leptospiral surface. We determine the capacity of these proteins to bind to host tissue components by enzyme-linked
immunosorbent assay. OmpL37 binds elastin preferentially, exhibiting dose-dependent, saturating binding to human skin
(Kd, 104619 nM) and aortic elastin (Kd, 152627 nM). It also binds fibrinogen (Kd, 244615 nM), fibrinogen fragment D (Kd,
132630 nM), plasma fibronectin (Kd, 359668 nM), and murine laminin (Kd, 410681 nM). The binding to human skin elastin
by both recombinant OmpL37 and live Leptospira interrogans is specifically enhanced by rabbit antiserum for OmpL37,
suggesting the involvement of OmpL37 in leptospiral binding to elastin and also the possibility that host-generated
antibodies may promote rather than inhibit the adherence of leptospires to elastin-rich tissues. Further, we demonstrate
that OmpL37 is recognized by acute and convalescent leptospirosis patient sera and also by Leptospira-infected hamster
sera. Finally, OmpL37 protein is detected in pathogenic Leptospira serovars and not in saprophytic Leptospira. Thus, OmpL37
is a novel elastin-binding protein of pathogenic Leptospira that may be promoting attachment of Leptospira to host tissues.
Citation: Pinne M, Choy HA, Haake DA (2010) The OmpL37 Surface-Exposed Protein Is Expressed by Pathogenic Leptospira during Infection and Binds Skin and
Vascular Elastin. PLoS Negl Trop Dis 4(9): e815. doi:10.1371/journal.pntd.0000815
Editor: Mathieu Picardeau, Institut Pasteur, France
Received April 2, 2010; Accepted August 9, 2010; Published September 7, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This work was supported by Public Health Service grant AI-34431 (to D.A.H.) from the National Institute of Allergy and Infectious Diseases and by VA
Medical Research Funds (to D.A.H.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: D.H. and H.C. are coauthors on a manuscript in preparation with Associate Editor Mathieu Picardeau. D.A.H. is a consultant for Merial,
which markets vaccines for prevention of leptospirosis.
* E-mail: mpinne@ucla.edu
Introduction
Leptospirosis is a zoonosis caused by pathogenic Leptospira spp.
transmitted from reservoir hosts (typically rodents) to humans via
water contaminated by infected animals and has a significant
impact on public health throughout the developing world [1–4].
Leptospirosis also has significant adverse effects on the agricultural
industry by causing abortions, infertility, and death in livestock
[5,6]. After being shed in the urine of a reservoir host animal,
leptospires can persist in freshwater or soil until contact with
abraded skin or mucous membranes of a new host occurs. The
resulting infection is potentially fatal, and is frequently character-
ized by jaundice, renal failure, and/or pulmonary hemorrhage
[1,4,7]. Large outbreaks of leptospirosis occur in tropical and
subtropical regions after heavy rainfall and the dispersal of
leptospires in contaminated water [3,8]. Current vaccines against
leptospirosis target the lipopolysaccharide (LPS) coat of the
leptospires, which is highly variable; this variation is thought to
be the major antigenic determinant defining the differences
between approximately 230 serovars that contribute to serovar-
specific immunity [6,9]. In contrast, vaccines directed towards
well-conserved leptospiral outer membrane proteins (OMPs)
[10,11] would have an advantage in inducing cross-protective
immunity [12].
The leptospiral lifecycle involves interactions with host tissues at
multiple stages of infection, including: (i) entering the host, (ii)
evading its immune response, and (iii) adhering to tissues [13–15].
Identification and characterization of novel proteins that mediate
the stage-specific interactions with the host are essential for the
understanding of leptospiral pathogenesis, and in the development
of diagnostic and protective antigens for leptospirosis. Pathogenic
leptospires have been shown to bind to a variety of host ligands,
including fibronectin, fibrinogen, collagen, laminin, elastin, and
proteoglycans, indicating that cell surface and extracellular matrix
(ECM)-binding OMPs, or adhesins, are likely to be expressed by
the spirochetes [16–21]. It is possible that leptospires express
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attachment, dissemination, and colonization. Many leptospiral
proteins, including LigA/B, Lsa21, Lsa27, Lsa63, Lsa24 (LfhA/
LenA), LenB to F, LipL32, Lp95, TlyC, and LipL53, have been
shown to have affinity for host ligands in vitro [18,19,21–32].
However, it is unclear to what extent these putative adhesins
mediate interactions of leptospires with cell surface and ECM
proteins. Only Lsa24, LigA/B, and Lsa63 have been tested for
their capacity to inhibit leptospiral adherence to ECM proteins
[18,21,24,32]. In each case, only partial inhibition was observed,
suggesting that additional fibronectin-, laminin-, collagen-, and
elastin-binding proteins likely exist in Leptospira [18,21,24,32].
In this study, we investigated whether the surface-exposed
proteins in Leptospira, OmpL36 (LIC13166), OmpL37 (LIC12263),
and OmpL47 (LIC13050) that we recently described [33] can bind
to any host ligands. We now report that OmpL37 is the first
leptospiral protein found to have pronounced specificity for
human skin elastin. OmpL37 exhibits strong, saturating binding
to skin elastin with one of the highest affinities of all leptospiral
ligand-binding proteins described. In addition, OmpL37 binds
efficiently to human aortic elastin, fibrinogen, fibrinogen fragment
D, and to a lesser extent laminin and plasma fibronectin. OmpL47
also binds to laminin, plasma fibronectin, fibrinogen, fibrinogen
fragment D, along with collagen type III, and aortic elastin, but
showing much lower activities than OmpL37. OmpL36 shows no
binding to any of the host tissue components investigated.
Elastin is a connective tissue component of ECM responsible for
the elasticity and resilience of skin, lung, blood vessels, uterus,
placenta, and other tissues [34–36]. These elastin-rich tissues are
highly relevant to leptospirosis as infection includes entry through
skin abrasions or mucous membranes, dissemination through the
circulation, and attachment to vascular, renal, pulmonary, uterine,
and other tissues. Until our discovery of the elastin-binding
properties of OmpL37, only LigB was known to have the capacity
to bind elastin and tropoelastin [21]. We also show that OmpL37
antiserum can enhance the binding to skin elastin by both live
Leptospira and recombinant OmpL37, suggesting that leptospiral
binding to elastin is at least partially mediated by OmpL37.
Expression of OmpL37 during infection is confirmed with the
recognition of OmpL37 by sera from Leptospira-infected hamsters
and also acute and convalescent leptospirosis patients. While the
gene for an OmpL37 homologue is present in saprophytic
leptospires, OmpL37 is detectable only in pathogenic Leptospira
serovars. Taken together, our data suggest that OmpL37 is an
elastin-binding protein of Leptospira with potential roles in
leptospirosis, including the attachment to elastin-rich tissues, such
as the dermis, vasculature, and lungs.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the Research and Development
Committee, VA Greater Los Angeles Healthcare System,
Research Service (PCC # 2008-121778).
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal work was approved by the VA
Greater Los Angeles Healthcare System, Research Service (PCC
# 2009-010088).
Bacterial strains and growth conditions
Leptospira interrogans serovar Copenhageni strain Fiocruz L1-130
was isolated from a patient during a leptospirosis outbreak in
Salvador, Brazil [8]. L. interrogans serovar Pomona strain PO-01, L.
kirscheneri serovars Mazdok strain 5621 and Grippotyphosa strain
RM52, L. borgpetersenii serovars Tarrasovi strain Perepelicin and
Javanica strain Veldrat Bataviae 46, Leptonema illini strain 3055,
Leptospira weilii serovar Celledoni strain Celledoni, L. wolbachii
serovar Biflexa strain codice, L. inadai serovar Lyme strain 10, and
L. biflexa serovar Patoc strain Patoc 1 were obtained from the
National Leptospirosis Reference Center (National Animal
Disease Center, Agricultural Research Service, U.S. Department
of Agriculture, Ames, Iowa). Leptospires were cultivated in
Ellinghausen-McCullough-Johnson-Harris (EMJH) medium sup-
plemented with 1% rabbit serum (Rockland Immunochemicals,
Gilbertsville, PA) and 100 mg/ml 5-fluorouracil at 30uC [37].
Antibodies and serum samples
The polyclonal rabbit sera specific for OmpL37, OmpL47, and
OmpL54 have been described previously [33]. Immunoglobulins
G (IgG) from OmpL37 and OmpL47 antisera were purified by
Melon Gel IgG spin purification kit (Thermo Scientific, Rockford,
IL) according to manufacturer’s instructions. LipL32 monoclonal
antibody 1D9 [38,39] was a kind gift from Dr. Jose ´ Antonio
Guimara ˜es Aleixo (Universidade Federal De Pelotas, Pelotas,
Brazil). Pooled sera from infected Syrian hamsters (Harlan
Laboratories) were obtained ten days following intradermal
challenge of one month-old animals with L. interrogans L1-130.
As a negative control, a serum sample from a hamster injected
intradermally with EMJH was collected after 12 days. Patient sera
from leptospirosis outbreaks in 1996 and 1997 in Salvador, Brazil,
were kindly provided by Dr. Albert I. Ko (Oswaldo Cruz
Foundation, Salvador, Bahia, Brazil). Acute and convalescent
samples from the same patients were prepared by pooling sera
from 13 individuals with laboratory-confirmed leptospirosis.
Normal human serum was obtained from Thermo Scientific and
Millipore (Billerica, MA).
Author Summary
Leptospirosis is a potentially fatal disease in humans and
livestock caused by Leptospira bacteria. Effective antibiotic
treatment depends on timely, accurate diagnosis. Howev-
er, current diagnostic and vaccine options are limited by
their specificity for the lipid-sugar coat of leptospires,
which varies among 200 serum-reactive groups. We aim to
understand how leptospires infect a host, and in turn, to
develop broadly effective diagnostic and immunization
products. We recently described OmpL37, a new protein
on the surface of leptospires. Here, we show it is made by
pathogenic strains, suggesting it can be a target for
detecting and protecting against a wide range of
Leptospira. Moreover, leptospirosis patients and hamsters
infected with leptospires make antibodies against
OmpL37. Purified OmpL37 binds host proteins, including
human elastin, fibrinogen, fibronectin, and mouse laminin.
Although other leptospiral proteins bind multiple host
proteins, OmpL37 has novel preferential affinity for skin
and aorta elastin, suggesting a role in a common route of
transmission through abraded skin and exposed blood
vessels. Indeed, OmpL37 binding and leptospiral attach-
ment to elastin are both enhanced by OmpL37 antiserum,
further implicating a possible role for OmpL37 during
infection. Thus, OmpL37 may mediate host attachment
and has potential clinical application with a broad range of
Leptospira.
Elastin-Binding by OmpL37 of Pathogenic Leptospira
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LIC10091
T h eg e n ee n c o d i n gp o t e n t i a lo u t e rm e m b r a n el i p o p r o t e i n ,
LIC10091 (LipL40) [40], was amplified from Fiocruz L1-130 DNA
using forward primer, 59- TTCGCATATGAAAACGCCTC-
CTCCTAAAG -39, and reverse primer, 59- TAAAATCTC-
GAGTTTCAAAACTTCTACGGGC- 39, by PCR conditions as
described for ompL36, ompL37, and ompL47 [33]. PCR product was
digested with NdeIa n dXhoI (New England BioLabs, Ipswich, MA),
cloned into NdeI- and XhoI- digested expression vector, pET-20b(+)
(Novagen, San Diego, CA), and purified as previously described for
OmpL36, OmpL37, and OmpL47 [33].
Gel electrophoresis and immunoblotting
Protein samples were boiled for 5 min in Novex NuPAGE
sample buffer (Invitrogen, Carlsbad, CA) in the presence of 2.5%
b-mercapthoethanol and separated in Bis-Tris 4–12% polyacryl-
amide gradient NuPAGE gels (Invitrogen).
For immunoblotting, proteins were transferred to a polyviny-
lidene difluoride (PVDF) Immobilon-P membrane (Millipore) and
probed with rabbit polyclonal antisera, Syrian hamster sera, or
leptospirosis patient sera. Bound antibodies were detected using
horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (GE
Lifesciences, Buckinghamshire, England), anti-Syrian hamster IgG
(Jackson Immuno Research, West Groove, PA), or anti-human
IgG (Sigma-Aldrich, St. Louis, MO), respectively. Immunoblots
were visualized by enhanced chemiluminescence reagents accord-
ing to the manufacturer’s instructions (Thermo Scientific).
Enzyme-linked immunosorbent assay (ELISA) of binding
to host ligands by OmpL proteins
Host ligands included human plasma fibronectin (Sigma-
Aldrich), human plasma fibronectin 30-kDa proteolytic fragment
(heparin-binding domain, Sigma-Aldrich), human plasma fibro-
nectin 45-kDa proteolytic fragment (gelatin-binding domain,
Sigma-Aldrich), human fibroblast fibronectin (Calbiochem, La
Jolla, CA), human plasma fibrinogen (HYPHEN BioMed, France),
human plasma fibrinogen fragment D (HYPHEN BioMed),
murine laminin (Sigma-Aldrich), bovine skin collagen type I
(Sigma-Aldrich), human placenta collagen type III (Sigma-
Aldrich), human placenta collagen type IV (Sigma-Aldrich),
soluble human skin elastin (Elastin Products Company, Owens-
ville, MO), soluble human aorta elastin (Sigma-Aldrich), bovine
kidney heparan sulfate (Sigma-Aldrich), shark cartilage chondroi-
tin sulfate (Sigma-Aldrich), fetal calf serum fetuin (Sigma-Aldrich),
and bovine serum albumin (BSA, Sigma-Aldrich). Ultra-high
binding Immulon 4HBX microtiter plates (Thermo Scientific)
were coated with 1 mg of host ligand in 0.1 ml of phosphate
buffered saline (PBS), pH 7.2, and incubated overnight at 4uC.
Fresh (stored for less than 4 months at 4uC) recombinant
OmpL36, OmpL37, OmpL47 [33], and LIC10091 (used as a
negative control) binding to individual ligands was assessed by
ELISA. Briefly, non-specific binding sites were blocked with
Protein-Free Blocking buffer (PFBb; Thermo Scientific) for 1 h at
room temperature and 1 mg of recombinant protein in 0.1 ml of
PFBb was added per well and incubated for 1 h at 37uC. For
assays of ligand binding as a function of leptospiral protein
concentration, serial dilutions of recombinant OmpL37 and
OmpL36 (negative control) ranging from 0 to 2 mM in 0.1 ml of
PFBb were added to wells and incubated for 1 h at 37uC. Wells
were washed three times with PBS, pH 7.2, and bound protein
was detected by probing with anti-His Tag monoclonal antibody
(5 Prime, Gaithersburg, MD), developing with HRP-conjugated
anti-mouse IgG (Novagen) and a tetramethyl benzidine substrate
(Thermo Scientific), and recording by spectrophotometry at
450 nm. For saturating binding the apparent dissociation constant
(Kd) was estimated as the concentration of OmpL37 resulting in
half-maximal binding.
For assays assessing effects of antibodies on binding of
recombinant OmpL37 to skin elastin, recombinant OmpL37
was pre-incubated either with serum against OmpL37 or OmpL47
(negative control) at 1:2500 dilution or purified IgG at 1:40 to
1:640 serial dilutions in PFBb at room temperature for 30 min. In
addition, OmpL37 was pre-incubated with convalescent leptospi-
rosis patient sera or Leptospira-infected hamster sera at 1:640 to
1:10,240 serial dilutions in PFBb at room temperature for 1 h.
Then mixtures containing 0.5 mg of OmpL37 in 0.1 ml of PFBb
were added to microtiter wells, incubated for 1 h at 37uC, and
bound protein detected as described above.
ELISA of immobilized OmpL37 binding to freely soluble
host ligands
Onemg of recombinant OmpL37 or OmpL36 (negative control)
in 0.1 ml PBS, pH 7.2, was used to coat Immulon 4HBX
microtiter wells overnight at 4uC. Non-specific binding sites were
blocked with PFBb and 1 mg of human plasma fibronectin, human
plasma fibrinogen, human plasma fibrinogen fragment D, murine
laminin, bovine skin collagen type I, human collagen type IV, or
human skin elastin in 0.1 ml of PFBb was added and incubated for
1 h at room temperature. After three washes with PBS, pH 7.2,
OmpL37-bound host ligands were detected by probing with anti-
human fibronectin rabbit antibody (Sigma-Aldrich), anti-human
fibrinogen rabbit IgG (HYPHEN BioMed), anti-laminin rabbit
IgG (Sigma-Aldrich), anti-collagen type I monoclonal antibody
(Clone COL-1, Sigma-Aldrich), anti-collagen type IV monoclonal
antibody (Clone COL-94, Sigma-Aldrich), or anti-elastin rabbit
IgG (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), then
adding HRP-conjugated anti-mouse IgG (Novagen) or HRP-
conjugated anti-rabbit IgG (GE Lifesciences) and developing as
described above.
ELISA of leptospiral binding to skin elastin
Microtiter plates were coated with human skin elastin and non-
specific binding sites were blocked as described above. L. interrogans
cultures were harvested by centrifugation at 20006g for 15 min at
room temperature and resuspended in PBS-5 mM MgCl2 to a
final concentration of 1610
9 cells/ml. To assess the effect of the
OmpL37 antibodies on leptospiral binding to elastin, serial
dilutions (1:40 to 1:1280) of anti-OmpL37 or anti-OmpL54 (used
as a negative control) were mixed with the leptospires or PBS-
5 mM MgCl2 and 1610
8 cells in 0.1 ml of PBS-5 mM MgCl2
were added to the microtiter wells. For experiments assessing the
inhibition of leptospiral binding by recombinant OmpL37, prior
to the addition of leptospires, 0.5 mM of recombinant protein in
0.1 ml of PFBb was either added directly to elastin-coated
microtiter wells or pre-incubated with anti-OmpL37 or anti-
OmpL47 (negative control) at a 1:500 dilution for 30 min at room
temperature and added to the microtiter wells. Plates were
incubated for 1 h at 37uC, and washed three times with PBS. After
addition of leptospires, plates were incubated at 30uC for 90 min,
unbound leptospires were removed by four washes with PBS-
5 mM MgCl2, and adherent cells were fixed with methanol at
220uC for 10 min. Elastin-bound leptospires were detected by
probing with LipL32 monoclonal antibody 1D9 and developing as
described above.
To measure the effect of OmpL37 antibodies on the binding of
immobilized leptospires to freely soluble skin elastin, 1610
8 of L.
Elastin-Binding by OmpL37 of Pathogenic Leptospira
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Immulon 4HBX microtiter wells for 90 min at 30uC, washed
twice with PBS-5 mM MgCl2, and non-specific binding sites were
blocked with PFBb for 30 min at room temperature. Rabbit sera
for OmpL37 and OmpL47 (negative control) diluted 1:40 and
1:2560 in PBS-5 mM MgCl2 were added to the wells and
incubated for 90 min at room temperature, followed by three
washes with PBS-5 mM MgCl2. One mg of human skin elastin in
0.1 ml PBS-5 mM MgCl2 was added and incubated overnight at
4uC. Wells were washed three times with PBS, pH 7.2, and cell-
bound complexes were fixed with methanol at 220uC for 10 min,
followed by additional blocking with PFBb. Leptospira-bound
elastin was detected by probing with anti-elastin mouse serum
(Novus Biologicals, Littleton, CO) and developing as described
above.
Results
Recombinant OmpL37 binds host tissue components
To investigate the capacities of our recently described surface-
exposed transmembrane OmpL proteins [33] to interact with host
tissue ligands, soluble recombinant OmpL36, OmpL37, and
OmpL47 were assessed for binding to immobilized host
components. BSA and the highly glycosylated serum protein,
fetuin, were used as controls for non-specific binding. Soluble
recombinant LIC10091 was used as a non-binding protein
control. OmpL37 exhibited significant binding to ECM compo-
nents, such as human skin (P,0.001 compared to BSA) and aorta
elastin (P,0.001), laminin (P,0.001), fibrinogen (P,0.01),
fibrinogen fragment D (P,0.001), and plasma fibronectin
(P,0.05) (Fig. 1). OmpL37 binding to the 30-kDa and 45-kDa
fragments of plasma fibronectin, fibroblast fibronectin, collagen
types I, III, and IV, heparan sulfate, and chondroitin sulfate was
not statistically significant (Fig. 1). OmpL47 also showed
significant binding to laminin (P,0.001), fibrinogen (P,0.001),
fibrinogen fragment D (P,0.001), plasma fibronectin (P,0.001),
collagen III (P,0.001), and aorta elastin (P,0.05). However, the
OmpL47 activities were much lower than those observed for
OmpL37 and were not investigated further. None of the other
recombinant proteins exhibited significant binding to any of the
host tissue components investigated (Fig. 1).
In order to compare binding affinities, the interaction with
immobilized skin and aorta elastin, fibrinogen, fibrinogen
fragment D, plasma fibronectin, plasma fibronectin 30-kDa and
45-kDa fragments, and laminin was measured as a function of
OmpL37 concentration from 0 to 2 mM (Fig. 2 and Table 1).
OmpL37 exhibited very strong, saturating binding to skin elastin
(Kd , 104619 nM), aorta elastin (Kd , 152627 nM), fibrinogen
(Kd , 244615 nM), and fibrinogen fragment D (Kd , 132630 nM)
as estimated by ELISA from three independent experiments.
OmpL37 binding to plasma fibronectin (Kd , 359668 nM), its 30-
kDa (Kd , 408694 nM) and 45-kDa fragment (Kd , 460670 nM),
and laminin (Kd , 410681 nM) were noticeably lower (Fig. 2 and
Table 1). OmpL36 was used as a negative control based on our
observation that OmpL36 does not bind to host ligands (Fig. 1).
The comparison of apparent Kds for the saturation binding of host
proteins by recombinant OmpL37 is summarized in Table 1.
In addition, we investigated whether OmpL37 immobilized on
microtiter wells bound freely soluble host proteins (Fig. 3).
Immobilized OmpL37 exhibited significant binding to free
laminin (P,0.001 compared to collagen IV), human skin elastin
(P,0.001), and plasma fibronectin (P,0.05) (Fig. 3). It is evident
that immobilized OmpL37 binds to virtually the same host
proteins as freely soluble OmpL37, with the exception of
fibrinogen and fibrinogen fragment D (Fig. 1 and 3). Although
immobilized OmpL37 can bind to freely soluble ligands, the
interaction appears to be weaker when compared to that of free
OmpL37 binding to immobilized ligands (Fig. 1 and 3). This could
be due to an impairment of the active conformation of OmpL37
caused by its immobilization to the microtiter wells, to the
differences between antibodies utilized for detection or to the
intrinsic property of less efficient binding of soluble versus
immobilized host proteins, which has been described for
pathogenic bacteria and their surface proteins [41–43].
OmpL37 antiserum enhances leptospiral binding to skin
elastin
We examined whether OmpL37 mediates the attachment of
leptospires to human skin elastin by testing for OmpL37
antiserum inhibition of live Leptospira binding to immobilized
skin elastin in an ELISA. Surprisingly, the OmpL37 antiserum
enhanced adhesion in a dose-dependent manner, whereas
antiserum for another surface-exposed OMP, OmpL54, had no
effect (Fig. 4A). Leptospiral binding to skin elastin was enhanced
by the OmpL37 antiserum at dilutions of 1:40 (1.6-fold compared
to no antibody, P,0.001), 1:80 (1.5-fold, P,0.001), and 1:160
(1.3-fold, P,0.05); the effect was not evident at higher dilutions
(Fig. 4A). The increase in adhesion was not due to leptospiral
agglutination as determined with a systematic examination for
the presence of leptospiral aggregates or decrease in leptospiral
numbers in multiple fields by dark-field microscopy (data not
shown). We also investigated the effect of OmpL37 antiserum on
the binding to free skin elastin by Leptospira immobilized on
microtiter wells and found that a 1:40 dilution of antiserum
increased binding 1.4-fold (data not shown). Further, we assessed
the effect of the OmpL37 antibodies on the binding of
recombinant OmpL37 to skin elastin (Fig. 4B). The OmpL37
antiserum significantly enhanced recombinant OmpL37 binding
to skin elastin at a dilution of 1:2500 (1.4-fold, P,0.05), a .10-
fold lower antiserum concentration compared to that required for
an effect on the adhesion of leptospires (Fig. 4A and 4B). IgG
purified from the OmpL37 antiserum slightly enhanced (1.2-fold)
OmpL37 binding to skin elastin at dilutions of 1:40 to 1:160
(Fig. 4B); however the effect was not statistically significant
(P.0.05), indicating the possibility that along with OmpL37-
specific antibody, another serum component removed in the
purification of IgG could be required for binding enhancement.
The antiserum and purified IgG for another surface-exposed
OMP, OmpL47, was used as a negative control and did not have
any effect on OmpL37 binding (Fig. 4B). The OmpL37
antiserum did not exhibit any statistically significant effect on
recombinant OmpL37 binding to fibronectin, fibrinogen, and
laminin (data not shown). Further, we investigated whether
convalescent leptospirosis patient sera enhance leptospiral
binding to skin elastin. Dark-field microscopy revealed leptospiral
agglutination by patient sera (data not shown), which prevented
the assessment of leptospiral adhesion. We also investigated the
effects of convalescent leptospirosis patient sera and Leptospira-
infected hamster sera on recombinant OmpL37 binding to skin
elastin but no statistically significant enhancement was observed
(Fig. S1 and S2). We also tested for the inhibition of leptospiral
binding to skin elastin by pre-treating the wells with a saturating
concentration (0.5 mM) of recombinant OmpL37 alone or pre-
incubated with the OmpL37 antiserum and found no effect (Fig.
S3), indicating that additional leptospiral surface proteins could
mediate elastin binding or that the avidities of recombinant and
native cellular OmpL37 are significantly different.
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To investigate whether OmpL37 can elicit an immune response
from an infected host, we examined the reactivity of sera from L.
interrogans L1-130-infected hamsters and leptospirosis patients to
recombinant OmpL37 by immunoblot (Fig. 5). The results show
that sera pooled from two L1-130-infected hamsters recognized
OmpL37 and OmpL36 but not OmpL47 (Fig. 5B). Control
hamster serum obtained after sham infection with sterile EMJH
medium did not react to any of the proteins tested (Fig. 5B).
Similar results were obtained when sera from acute and
convalescent leptospirosis patients were tested (Fig. 5C). Pooled
sera from 13 individuals diagnosed with either acute leptospirosis
or recovering from the disease recognized OmpL37 and OmpL36,
while no significant reactivity was found for OmpL47 and pooled
normal human serum did not react to any of these proteins
(Fig. 5C).
OmpL37 is detected in pathogenic but not saprophytic
Leptospira serovars
The expression of OmpL37 by pathogenic and saprophytic
Leptospira serovars was investigated by immunoblot using OmpL37
antiserum (Fig. 6A). Pathogenic Leptospira included L. interrogans
serovars Copenhageni strain Fiocruz L1-130 and Pomona strain
PO-01, L. kirschneri serovars Mazdok strain 5621 and Grippoty-
phosa strain RM 52, and L. borgpetersenii serovars Tarrasovi strain
Figure 1. Binding of recombinant Omp36, OmpL37, and OmpL47 to host tissue components. Microtiter wells were coated with 1 mgo f
plasma fibronectin (Fn), fibroblast cellular fibronectin (Fnc), heparin-binding domain of plasma fibronectin (Fn-30 kDa), gelatin-binding domain of
plasma fibronectin (Fn-45 kDa), plasma fibrinogen (Fg), plasma fibrinogen fragment D (Fg-D), laminin (Lm), collagen type I (Col I), collagen type III (Col
III), collagen type IV (Col IV), kidney heparan sulfate (Heparan. S.), cartilage chondroitin sulfate (Chondr. S.), aorta elastin, skin elastin, fetuin, and BSA.
One microgram of recombinant protein was added per well and binding was measured by ELISA. Data represent the mean absorbance at 450 nm 6
the standard deviation of three independent experiments. The binding of recombinant proteins to tissue components was compared to their binding
to BSA by Student’s two-tailed t test (*** P,0.001, ** P,0.01, * P,0.05).
doi:10.1371/journal.pntd.0000815.g001
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www.plosntds.org 5 September 2010 | Volume 4 | Issue 9 | e815Figure 2. Binding to skin and aorta elastin, fibrinogen, fibrinogen fragment D, fibronectin, and laminin as a function of OmpL37
concentration. Binding of OmpL37 (concentration ranging from 0 to 2 mM) to 1 mg of immobilized (A) human skin elastin, (B) human aorta elastin,
(C) human plasma fibrinogen, (D) human plasma fibrinogen fragment D, (E) human plasma fibronectin, and (F) murine laminin was measured by
ELISA. The mean optical density at 450 nm 6 the standard deviation of three independent experiments is shown at each point. The apparent Kd for
saturating binding was estimated as the concentration of recombinant OmpL37 resulting in half-maximal binding (see text and Table 1). OmpL36
served as a negative control.
doi:10.1371/journal.pntd.0000815.g002
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Leptospira and Leptonema included Leptonema illini strain 3055,
Leptospira weilii serovar Celledoni strain Celledoni, L. wolbachii
serovar Biflexa strain codice, L. inadai serovar Lyme strain 10, and
L. biflexa serovar Patoc strain Patoc 1. Loading of equal amounts of
proteins from whole cell lysates was confirmed by Coomassie
Brilliant G-250 staining (6B). As expected, the immunoblot
revealed the highest reactivity of OmpL37 antibodies against L.
interrogans L1-130 (Fig. 6A). OmpL37 was detected in all other
pathogenic Leptospira strains investigated with various levels of
band intensity reflecting variations in either expression or
antiserum reactivity (Fig. 6A). Interestingly, the OmpL37 homolog
in L. interrogans serovar Pomona (LIP_1392, 99% identity) is
expressed in considerably lower amounts (Fig. 6A). OmpL37 was
not detected in any saprophytic strains investigated, with the
exception of Leptonema illini, where a very weak band could be
detected (Fig. 6A). In L. biflexa a homolog of OmpL37 has been
annotated (LBF_0995), but the amino acid sequence reveals only
47% identity (Fig. S4), and is either not recognized by the
OmpL37 antibodies or is not expressed in L. biflexa under the in
vitro conditions used (Fig. 6A). The genomes of the other Leptospira
serovars we tested have not been sequenced precluding identifi-
cation of OmpL37 homologues in those organisms. Taken
together, our results show that OmpL37 was detectable only in
pathogenic Leptospira spp.
Discussion
Bacterial adhesins are surface-exposed OMPs, often playing
roles as determinants of pathogenicity that allow bacteria to
colonize host tissues by attaching to host molecules, such as ECM
proteins [14,15]. L. interrogans is an extracellular pathogen that
enters the susceptible host through skin abrasions and mucous
membranes, disseminates through the bloodstream, and colonizes
kidneys, lungs, and other organs. The capacity of L. interrogans to
adhere to tissues of various organs requires surface-exposed
proteins with high affinity for host cell-surface and ECM
components. The abundance of elastin in the inner layers of skin
(reticular region of the dermis), blood vessels, and lungs implies
that Leptospira have the ability to recognize and attach to elastin.
Whereas various leptospiral proteins have been shown to have the
capacity to bind multiple ECM components, such as laminin,
fibronectin, fibrinogen, and collagens [18,19,22–30,32], only the
LigB repeated domains have been shown to exhibit elastin-binding
activity [21]. Thus, it is of interest to identify any additional
elastin-binding proteins. We previously identified four novel
surface-exposed transmembrane OMPs, OmpL36, OmpL37,
OmpL47, and OmpL54 [33] and have been investigating whether
these proteins bind to host proteins. The recombinant OmpL36,
OmpL37, and OmpL47 proteins are soluble and suitable for
functional analysis by ELISA.
The binding activity of OmpL37 for the host components tested
varied widely, with the most significant binding to human skin
elastin, followed by human aorta elastin, laminin, fibrinogen
fragment D, fibrinogen, and plasma fibronectin (Fig. 1). The
weakest binding was observed for chondroitin sulfate, heparan
sulfate, and collagen type IV (Fig. 1). Although we used BSA as a
widely accepted negative control for host-ligand binding, it is
important to note that albumin occurs in blood and the OmpL37
binding observed with BSA and fetuin may be important in host-
pathogen interactions that require further investigation. This is the
first report of a leptospiral protein showing pronounced specificity
for human skin elastin. The strong dose-dependent, saturating
binding to skin elastin gave an estimated apparent Kd of




b Elastin, aorta Fibrinogen Fg-D Fn Fn-30 kDa Fn-45 kDa Laminin BSA
104619 152627 244615 132630 359668 408694 460670 410681 NS
aEstimated as nanomolar concentration at half-maximal binding by OmpL37. NS, not saturating.
bAbbreviations: Fg-D, fibrinogen fragment D; Fn, plasma fibronectin; Fn-30 kDa, plasma fibronectin 30 kDa fragment (heparin-binding domain); Fn-45 kDa, plasma
fibronectin 45 kDa fragment (gelatin-binding domain).
doi:10.1371/journal.pntd.0000815.t001
Figure 3. Binding of immobilized OmpL37 to freely soluble
host proteins. Microtiter plates were coated with 1 mg of recombinant
OmpL37 or OmpL36. One mg of plasma fibronectin (Fn), plasma
fibrinogen (Fg), plasma fibrinogen fragment D (Fg-D), laminin (Lm),
collagen type I (Col I), collagen type IV (Col IV), or skin elastin was added
per well and binding was measured by ELISA. Data represent the mean
absorbance at 450 nm 6 the standard deviation from triplicate wells.
The binding of recombinant OmpL37 to tissue components was
compared to its binding to collagen type IV, which was chosen as a host
protein control for non-specific binding based on our data in Fig. 1, by
Student’s two-tailed t test (** P,0.001, * P,0.05).
doi:10.1371/journal.pntd.0000815.g003
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affinities for all leptospiral ligand-binding proteins investigated to
date, comparable to that of LigB U1 binding to fibronectin and
fibrinogen with Kd of 72.6611.7 nM and 87.162.4 nM,
respectively [18], LenB binding to fibronectin and laminin with
Kd of 10668 nM and 118639 nM, respectively [30], and LigB
Cen binding to lung elastin with Kd of 101611 nM [21]. It is
apparent that LigB exhibits strongest affinity for fibronectin and
fibrinogen when compared to its affinity for lung elastin and other
host proteins tested [18,21]. It is noteworthy that OmpL37 showed
much stronger affinity for human skin and aorta elastin (Fig. 2 and
Table 1) compared to the binding of lung elastin by multiple parts
of LigB, with the exception of LigB Cen [21].
Dose-dependent, saturating binding by OmpL37 was also
observed for fibrinogen and its fragment D, with considerably
weaker activity for plasma fibronectin and its 30-kDa and 45-kDa
fragments (Fig. 2 and Table 1). Note that whereas OmpL37
seemed to interact very efficiently with laminin (Fig. 1), the
reaction kinetics revealed barely saturating binding with Kd
greater than 410681 nM (Fig. 2 and Table 1). Our results show
that OmpL37 interacts with multiple host proteins, a property that
is common with previously characterized ligand-binding proteins
of Leptospira [18,19,22–30,32].
L. interrogans was recently shown to bind to elastin in vitro and
LigB has been attributed a partial role in this binding, and it was
proposed that there are additional elastin-binding proteins [21].
This observation and our results showing strong elastin binding by
recombinant OmpL37 prompted us to investigate the contribution
of OmpL37 to leptospiral adherence to elastin. The addition of
saturating amounts of recombinant OmpL37 did not affect L.
interrogans binding to immobilized human skin elastin, raising the
possibility that the avidity of recombinant OmpL37 for elastin is
Figure 4. Antiserum enhancement of binding by Leptospira and OmpL37 to skin elastin. Microtiter wells were coated with 1 mg of human
skin elastin and binding was measured by ELISA. (A) PBS-5 mM MgCl2 (no cells) or 1610
8 L. interrogans L1-130 in PBS-5 mM MgCl2 (cells) without
antiserum (no Ab) or in the presence of OmpL37 or OmpL54 antiserum (Ab) diluted 1:40, 1:80, 1:160, 1:320, and 1:1280 were added to the elastin-
coated wells. (B) Recombinant OmpL37 (0.5 mg) was preincubated with or without the IgG purified from 10 times diluted OmpL37 or OmpL47
antiserum at 1:40, 1:160, and 1:640 dilution and the OmpL37 or OmpL47 antiserum at 1:2500 dilution prior to addition to elastin-coated wells. Mean
absorbance at 450 nm 6 the standard deviation of a representative experiment performed in triplicate is shown. Statistical significance was
evaluated by one-way ANOVA comparing leptospiral or recombinant OmpL37 binding in the presence of antibodies compared with binding in the
absence of antibodies (** P,0.001, * P,0.05).
doi:10.1371/journal.pntd.0000815.g004
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affecting the ability of the recombinant protein to compete with
native OmpL37. However, we observed significant increases in
leptospiral elastin binding in the presence of rabbit antiserum for
OmpL37, with the effect being concentration dependent (Fig. 4A).
In contrast, antiserum for the surface-exposed OmpL54 did not
affect elastin binding by the spirochetes (Fig. 4A), suggesting that
antiserum specific for OmpL37 can promote the interaction of
OmpL37 on the cell surface with elastin. Convalescent leptospi-
rosis patient sera were also tested for effects on leptospiral binding
to elastin, but the strong agglutinating effect prevented assessment
of leptospiral adhesion.
Further, the OmpL37 antiserum but neither leptospirosis
patient sera nor Leptospira-infected hamster sera enhanced the
binding of recombinant OmpL37 to immobilized skin elastin
(Fig. 4B and Fig. S1–S2). The discrepancy might be due to the
different nature of the antibodies for OmpL37, with antibodies in
rabbit serum capable of recognizing additional epitopes not
recognized by antibodies generated in the infected hosts. As with
the enhancement of leptospiral adhesion, the effect on recombi-
nant OmpL37 was also specific for the OmpL37 antiserum, since
rabbit antiserum for OmpL47 did not produce an effect (Fig. 4B).
Interestingly, purified IgG specific for OmpL37 did not exhibit
statistically significant enhancement compared to that of antiserum
for OmpL37 (Fig. 4B). This discrepancy did not appear to be due
to inactivation of IgG molecules as we confirmed their recognition
of OmpL37 by immunoblot (data not shown). However, we
cannot exclude the possibility that some level of degradation or
partial loss of IgG activity could have occurred. The possibility
that the enhancement effect is due to another Ig type is not likely
as the IgG purification process also yields up to 20% of IgA and
IgM molecules. Since antisera for other surface-exposed lepto-
spiral proteins did not exhibit enhancement (Fig. 4A and B), we
hypothesize that another serum component in addition to
OmpL37 antibody might be required to enhance OmpL37
binding to elastin. Further, the OmpL37 antiserum did not
enhance recombinant OmpL37 binding to fibronectin, fibrinogen,
and laminin (data not shown), suggesting that this effect is specific
to elastin. Finally, the OmpL37 antiserum enhanced immobilized
Leptospira binding to freely soluble skin elastin (data not shown).
Figure 5. Host immune response to OmpL proteins. Recombinant OmpL47, OmpL37, and OmpL36 were separated by gel electrophoresis
(2.5 mg per lane), stained with Coomassie G-250 (A) or blotted onto PVDF membrane, and analyzed for serum reactivity. (B) Membranes probed with a
pool of two L. interrogans L1-130-infected hamster sera (1:1000) or non-infected control hamster serum (1:1000). (C) Membranes probed with normal,
acute, or convalescent pooled human sera (1:300). The positions of molecular mass standards (in kilodaltons) are indicated on the left.
doi:10.1371/journal.pntd.0000815.g005
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antibodies has been observed previously for fibronectin-binding
protein FnbA of Streptococcus dysgalactiae [44], fibronectin-binding
protein FnBPA of Staphylococcus aureus [45], and Lewis X (Le
x)
expressed by both human gastric mucosa and Helicobacter pylori
[46]. Antibodies recognizing the fibronectin-binding site, Au, of
FnbA bound to Au only in the presence of fibronectin [44].
Moreover, the Au antibodies enhanced ligand binding by
recombinant proteins or synthetic peptides containing the Au
sequence, suggesting that the antibodies can stabilize the ligand-
adhesin complex, resulting in enhanced fibronectin binding. This
would provide an advantage to the pathogen, where antibodies
could enhance adherence to host tissue rather than inhibit this
critical step in tissue colonization [44]. Interestingly, although the
fibronectin-binding repeats of FnBPA are recognized weakly by
antibodies in the absence of fibronectin, epitopes induced in
FnBPA by its interaction with fibronectin greatly enhance its
recognition by both monoclonal antibodies and sera from patients
with staphylococcal infections [45]. In H. pylori it has been shown
that Le
x antibodies can specifically increase bacterial adhesion
[46]. This potentially positive effect on colonization could be due
to an increase in bacterial aggregation or to the antibodies
mediating a bivalent H. pylori Le
x – antibody– human gastric
mucosa Le
x interaction that forms a bridge between bacteria and
host cells [46]. Our interesting but somewhat surprising finding
that OmpL37 antiserum enhances leptospiral binding suggests
that OmpL37 contributes to the adhesion of leptospires to skin
elastin. Since the OmpL37 antibodies do not promote leptospiral
agglutination, we hypothesize that they in conjunction with
another serum component alter the conformation of OmpL37 to
promote more efficient binding to elastin. Alternatively, the
antibodies may stabilize the elastin-OmpL37 complex as described
for FnbA [44], resulting in enhanced elastin binding and
leptospiral adhesion. The exact mechanism and functional role
of this enhancement needs further investigation, which is currently
under way in our laboratory.
To support our hypothesis that antibodies against OmpL37 may
aid Leptospira during the infection process, we wanted to verify that
there is a host immune response towards OmpL37. We found that
an antibody response to OmpL37 occurs in both the hamster
model and leptospirosis patients (acute and convalescent) (Fig. 5).
Further, we investigated whether OmpL37 is expressed in
pathogenic leptospiral isolates and found that OmpL37 could be
detected only in pathogenic Leptospira serovars (Fig. 6), albeit a
homologue is present in the L. biflexa genome (Fig. S4). Given that
the amino acid sequences of OmpL37 in serovars Copenhageni
and Pomona are 99% identical, the lower immunoblot reactivity
indicates that OmpL37 is expressed at much lower levels in
serovar Pomona (Fig. 6).
It has been reported that OmpL36 (LIC13166) and OmpL47
(LIC13050) are potential virulence factors of L. interrogans that are
recognized by leptospirosis patient sera [47]. However, we
observed the recognition of OmpL36 but not OmpL47 by the
sera from infected hosts (Fig. 5). This could be due to the different
techniques (ELISA versus immunoblot) employed in the studies. In
addition, proteomic analysis of total protein extracts separated by
2D-gel electrophoresis identified OmpL36 and OmpL47 along
with other well described leptospiral OMPs in virulent L. interrogans
serovar Pomona cultured from infected hamsters [48]. The failure
of these proteomic studies to detect OmpL37 may be explained by
another mass spectrometry study focusing on cellular protein
concentrations in L. interrogans serovar Copenhageni, which has
revealed that OmpL36 is the most abundant transmembrane
OMP (13
th highest of all cell proteins), OmpL47 is very abundant
(29
th highest), and OmpL37 is less abundant (204
th highest) [49].
The lower abundance of OmpL37 in serovar Copenhageni
compared to OmpL36 and OmpL47 and our data showing lower
expression of OmpL37 by serovar Pomona compared to serovar
Copenhageni suggest that there could be insufficient OmpL37 for
detection by proteomic analysis of total proteins separated by 2D-
gel electrophoresis. Although OmpL47 had very little ligand-
binding activity and OmpL36 did not show significant ligand-
binding activity (Fig. 1), the involvement of these proteins in
virulence awaits further investigation.
Based on the results presented here, we hypothesize that
OmpL37 might be involved in the pathogenesis of leptospirosis.
During the initial stage of infection, the strong binding affinity of
OmpL37 for human skin elastin would facilitate the attachment of
leptospires to an inner elastin-rich layer of the skin exposed by
abrasion. Later during dissemination, the ability of OmpL37 to
Figure 6. OmpL37 expression in pathogenic and saprophytic
isolates of Leptospira serovars. Extracts of 5610
7 leptospires per
lane were separated by gel electrophoresis, blotted onto PVDF
membrane, and probed with OmpL37 antiserum (1:1000) (A) or stained
with Coomassie G-250 (B). L. interrogans serovar Copenhageni strain
Fiocruz L1-130 (Lane 1), L. interrogans serovar Pomona strain PO-01
(Lane 2), L. kirscheneri serovar Mazdok strain 5621 (Lane 3), L. kirscheneri
serovar Grippotyphosa strain RM 52 (Lane 4), L. weilii serovar Celledoni
strain Celledoni (Lane 5), L. biflexa serovar Patoc strain Patoc 1 (Lane 6),
L. wolbachii serovar Biflexa strain codice (Lane 7), Leptonema illini strain
3055 (Lane 8), Leptospira inadai serovar Lyme strain 10 (Lane 9), L.
borgpetersenii serovar Tarrasovi strain Perepelicin (Lane 10), L.
borgpetersenii serovar Javanica strain Veldrat Bataviae 46 (Lane 11).
The saprophytic species in lanes 5 to 9 are indicated by asterisks. The
positions of molecular mass standards (in kilodaltons) are indicated on
the left.
doi:10.1371/journal.pntd.0000815.g006
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promote leptospiral attachment to elastin-rich vascular structures,
including the walls of the pulmonary, cardiac, and other blood
vessels, possibly explaining the propensity of leptospirosis to result in
hemorrhagic complications [1,50,51]. The enhancement of lepto-
spiral binding to elastin by OmpL37 antiserum supports the
hypothesis that the host immune response to OmpL37 could
promote rather than inhibit the adherence of infecting spirochetes
to elastin-rich tissues, possibly also aiding in evading immunological
clearance. Future studies are planned to map the elastin-binding sites
in OmpL37 to further understand the antiserum enhancement effect.
We also plan to identify the serum component that is apparently
required in addition to OmpL37 antibodies in the enhancement of
elastin-binding. Finally,we planto study the contribution of OmpL37
during the initial and subsequent stages of leptospirosis.
Supporting Information
Figure S1 Effects of convalescent leptospirosis patient sera on
recombinant OmpL37 binding to skin elastin. Microtiter wells
were coated with 1 mg of human skin elastin and binding was
measured by ELISA. Recombinant OmpL37 (0.5 mg) was
preincubated for 1 h at room temperature with convalescent
leptospirosis patient sera or normal human sera at 1:640, 1:2560,
and 1:10,240 dilution prior addition to elastin-coated wells. Mean
absorbance at 450 nm 6 the standard deviation of a represen-
tative experiment performed in triplicate is shown.
Found at: doi:10.1371/journal.pntd.0000815.s001 (0.20 MB PPT)
Figure S2 Effects of Leptospira-infected hamster sera on recombi-
nant OmpL37 binding to skin elastin. Microtiter wells were coated
with 1 mg of human skin elastin and binding was measured by
ELISA. Recombinant OmpL37 (0.5 mg) was preincubated for 1 h
at room temperature with Leptospira-infected hamster sera or normal
hamster sera at 1:640 and 1:2560 dilution prior addition to elastin-
coated wells. Mean absorbanceat 450 nm 6 the standard deviation
of a representative experiment performed in triplicate is shown.
Found at: doi:10.1371/journal.pntd.0000815.s002 (0.19 MB PPT)
Figure S3 Leptospiral binding to elastin after recombinant
OmpL37 has been pre-bound to elastin in presence of OmpL37
antiserum. Microtiter wells were coated with 1 mg of human skin
elastin and binding was measured by ELISA. Prior the addition of
leptospires (1.46108 per well), 0.5 mM of recombinant OmpL37
was either added directly to elastin-coated microtiter wells or pre-
incubated with anti-OmpL37 or anti-OmpL47 (negative control)
at a 1:500 dilution and added to the microtiter wells. Mean
absorbance at 450 nm 6 the standard deviation of a represen-
tative experiment performed in triplicate is shown. Statistical
significance was evaluated by one-way ANOVA comparing
leptospiral binding without recombinant OmpL37 compared with
binding after addition of recombinant OmpL37 (P.0.05).
Found at: doi:10.1371/journal.pntd.0000815.s003 (0.17 MB PPT)
Figure S4 Amino acid sequence homology of L. interrogans
OmpL37 (LIC12263) and L. biflexa LBF 0995. BLAST analysis
was performed between L. interrogans LIC12263 (OmpL37) and L.
biflexa genome. The highest scored homolog, LBF 0995 had 154/
326 identities (47%), 219/326 positives (67%) and 14/326 gaps
(4%).
Found at: doi:10.1371/journal.pntd.0000815.s004 (0.11 MB PPT)
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